Which Is More Clinically Relevant: End-of-Treatment or Off-Treatment Predictors of Hepatitis B Relapse and Surface Antigen Loss?

Gastroenterology. 2024 Jun;166(6):1193-1194. doi: 10.1053/j.gastro.2023.10.020. Epub 2023 Oct 26.

Authors

Dekai Zheng¹, Zhixin Fang¹, Jian Sun¹

Affiliation

¹ Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.

PMID: 37890561
DOI: 10.1053/j.gastro.2023.10.020

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents* / therapeutic use
Biomarkers / blood
Hepatitis B / diagnosis
Hepatitis B / drug therapy
Hepatitis B / virology
Hepatitis B Surface Antigens* / blood
Hepatitis B virus* / genetics
Hepatitis B virus* / immunology
Hepatitis B, Chronic* / blood
Hepatitis B, Chronic* / diagnosis
Hepatitis B, Chronic* / drug therapy
Hepatitis B, Chronic* / virology
Humans
Predictive Value of Tests
Recurrence*
Treatment Outcome